Spots Global Cancer Trial Database for Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)

Official Title: Spanish Lung Liquid vs. Invasive Biopsy Program

Study ID: NCT03248089

Conditions

Lung Cancer

Interventions

Guardant360

Study Description

Brief Summary: Tumor Derived cell free DNA (cfDNA) is increasingly used in the clinic to obtain genotype information about lung cancer, but its concordance with concurrent tumor-derived sequenced data is not known. The primary objective of this study is to demonstrate the non-inferiority of cfDNA-based versus tumor tissue-based genotyping.

Detailed Description: Primary objective: To demonstrate the non-inferiority of cfDNA-based versus tumor tissue-based genotyping as it pertains to the detection of clinically-actionable biomarkers in first line, treatment naïve, metastatic non-squamous NSCLC. The following secondary objectives will be studied: * Turn around Time (TAT) of cfDNA vs. tissue results. * Time to treatment (TtT) initiation. * Quantity not sufficient rate (QNS) of tissue for clinically-actionable biomarker testing. * Tumor Not Detected (TND) rate of cfDNA in blood. * Rescue rate of QNS samples using cfDNA-derived genotyping. * Rate response for patients that are actionable biomarker positive (either in cDNA or tissue) treated with target-drugs according investigator criteria. Up to three RECIST assessments per patient will be retrospectively done by external personnel (no investigational team). * Rate of discovery of genomically mediated, acquired resistance to targeted therapies in the biomarker-positive subsets.